Left atrium function in patients with coronary artery disease. 2014

Emanuela Facchini, and Anna Degiovanni, and Paolo N Marino
Department of Translational Medicine, Clinical Cardiology, Università del Piemonte Orientale, Azienda Ospedaliero Universitaria 'Maggiore della Carità', Novara, Italy.

OBJECTIVE The left atrial cavity has recently been identified as a potential biomarker for cardiac and cerebrovascular accidents. This review examines the potential of left atrial size and function in predicting cardiovascular disease in the general population and outcomes in coronary artery disease (CAD) patients. RESULTS The atrium is perfused primarily by branches of the proximal left circumflex coronary artery (LCx), and depression of the cavity mechanical performance has been demonstrated in experimental studies during LCx occlusion. Thus, left atrial volume and function assessment may have prognostic relevance, particularly in CAD patients. Such a line of thinking, however, is challenged by the widespread notion that the contribution by left atrial chamber morphology and functional quantitation to the risk stratification process after a first cardiovascular event is not adequately considered. However, a number of studies have shown that left atrial volume predicts survival and major adverse events after an acute myocardial infarction. Left atrial remodeling also provides an important overall prognostic information and correlates with brain natriuretic peptide after primary percutaneous coronary interventions. CONCLUSIONS Evaluation of left atrial size and function is currently of great interest and it will be more so in the very near future, given its potential for insights into the pathophysiology of the ischemic heart, which makes it an important clinical risk identifier in CAD patients.

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D003971 Diastole Post-systolic relaxation of the HEART, especially the HEART VENTRICLES. Diastoles
D006325 Heart Atria The chambers of the heart, to which the BLOOD returns from the circulation. Heart Atrium,Left Atrium,Right Atrium,Atria, Heart,Atrium, Heart,Atrium, Left,Atrium, Right
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013599 Systole Period of contraction of the HEART, especially of the HEART VENTRICLES. Systolic Time Interval,Interval, Systolic Time,Intervals, Systolic Time,Systoles,Systolic Time Intervals,Time Interval, Systolic,Time Intervals, Systolic
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016279 Atrial Function, Left The hemodynamic and electrophysiological action of the LEFT ATRIUM. Left Atrial Function,Atrial Functions, Left,Function, Left Atrial,Functions, Left Atrial,Left Atrial Functions
D020097 Natriuretic Peptide, Brain A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS. Brain Natriuretic Peptide,Nesiritide,B-Type Natriuretic Peptide,BNP Gene Product,BNP-32,Brain Natriuretic Peptide-32,Natrecor,Natriuretic Factor-32,Natriuretic Peptide Type-B,Type-B Natriuretic Peptide,Ventricular Natriuretic Peptide, B-type,BNP 32,Brain Natriuretic Peptide 32,Natriuretic Factor 32,Natriuretic Peptide Type B,Natriuretic Peptide, B-Type,Natriuretic Peptide, Type-B,Natriuretic Peptide-32, Brain,Peptide, Brain Natriuretic,Peptide-32, Brain Natriuretic,Type B Natriuretic Peptide,Ventricular Natriuretic Peptide, B type

Related Publications

Emanuela Facchini, and Anna Degiovanni, and Paolo N Marino
January 1973, Advances in cardiology,
Emanuela Facchini, and Anna Degiovanni, and Paolo N Marino
March 1966, The Journal-lancet,
Emanuela Facchini, and Anna Degiovanni, and Paolo N Marino
January 1980, Clinical and investigative medicine. Medecine clinique et experimentale,
Emanuela Facchini, and Anna Degiovanni, and Paolo N Marino
January 1981, Cor et vasa,
Emanuela Facchini, and Anna Degiovanni, and Paolo N Marino
May 1985, British heart journal,
Emanuela Facchini, and Anna Degiovanni, and Paolo N Marino
August 1985, American heart journal,
Emanuela Facchini, and Anna Degiovanni, and Paolo N Marino
March 1985, Journal of the American College of Cardiology,
Emanuela Facchini, and Anna Degiovanni, and Paolo N Marino
November 1984, European heart journal,
Emanuela Facchini, and Anna Degiovanni, and Paolo N Marino
January 1994, Cardiology,
Emanuela Facchini, and Anna Degiovanni, and Paolo N Marino
October 1987, European heart journal,
Copied contents to your clipboard!